SpareBank 1 SMN: Utstedelse av fondsobligasjonslån


SpareBank 1 SMN viser til børsmelding 1. oktober 2019, og banken har i dag utstedt et evigvarende fondsobligasjonslån (AT1) på NOK 250 millioner.

Oppgjørsdato for lånet er 15. oktober 2019.

Fondsobligasjonslånet har en kupong tilsvarende 3 måneders NIBOR + 3,25% p.a.
Første innløsningsrett for utsteder er etter 5 år, forutsatt Finanstilsynets godkjennelse.

Bankens Representantskap og Finanstilsynet har godkjent utstedelse av det nye obligasjonslånet.

SpareBank 1 Markets var tilrettelegger av transaksjonen.

Trondheim, 2. oktober 2019

Kontaktperson SpareBank 1 SMN:
Per Egil Aamo, Ass. finanssjef, tlf: 73 58 64 66

Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12

Om GlobeNewswire

One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Klövern signs two new rental contracts in Copenhagen24.11.2020 07:30:00 CETPress release

Klövern has signed a contract with Parfums Christian Dior for 973 sq.m. office space and a contract with Politiforbundet for 1,946 sq.m. office space in the so-called Codan-house on Gammel Kongevej in Copenhagen. Moving-in is estimated to be on 1 March 2021 and 1 June 2021, respectively. ”It is with great pleasure that we welcome our new tenants to the Codan-house where we have had a very great interest in rentals after our acquisition of the property. The Copenhagen rental market is strong and these lettings are steps in our plan to transform the property from a single-tenant property to an attractive modern multi-let property”, says Andreas Lange, Head of Klövern’s business unit Copenhagen. Klövern AB (publ) For additional information, please contact: Rutger Arnhult, CEO, +46 (0)70-458 24 70, Lars Norrby, IR, +46 (0)76-777 38 00, Klövern is a real estate company committed to working closely with customers to offer them attractive premi

Klövern tecknar två nya hyresavtal i Köpenhamn24.11.2020 07:30:00 CETPressemelding

Klövern har tecknat ett avtal med Parfums Christian Dior avseende 973 kvm kontorsyta och ett avtal med Politiforbundet avseende 1 946 kvm kontorsyta i det så kallade Codan-huset på Gammel Kongevej i Köpenhamn. Inflyttning beräknas ske den 1 mars 2021 respektive 1 juni 2021. ”Det är med stor glädje vi välkomnar våra nya hyresgäster till Codan-huset där vi haft ett mycket stort intresse för förhyrningar efter vårt förvärv av fastigheten. Köpenhamns hyresmarknad är stark och dessa uthyrningar är ett led i vår plan att ställa om fastigheten från en single-tenant-fastighet till en attraktiv modern mutli-let-fastighet”, säger Andreas Lange, Klöverns affärsenhetschef i Köpenhamn. Klövern AB (publ) För ytterligare information, vänligen kontakta: Rutger Arnhult, VD, 070-458 24 70, Lars Norrby, IR, 076-777 38 00, Klövern är ett fastighetsbolag som med närhet och engagemang erbjuder attraktiva lokaler i tillväxtregioner. Klövern är noterad på Nasda

Roche announces FDA approval of Xofluza for the prevention of influenza following contact with an infected person24.11.2020 07:00:00 CETPress release

Xofluza is the first single-dose influenza medicine approved to prevent influenza for those who have had contact with an infected person (post-exposure prophylaxis) Roche also provides an update on the sNDA filing for Xofluza in the paediatric setting Basel, 24 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza® (baloxavir marboxil) as a treatment to prevent influenza in people 12 years of age and older following contact with someone with influenza (known as post-exposure prophylaxis). Xofluza is the first single-dose influenza medicine approved for post-exposure prophylaxis. “With today’s approval, Xofluza is now available as the first single-dose, post-exposure preventive treatment for influenza,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We’re hopeful that reducing the burden of influenza ma

Novartis highlights confidence in growing sales with margin expansion, fueled by in-market brands and a rich pipeline, at Annual Meet the Management investor event24.11.2020 07:00:00 CETPress release

Novartis showcases unique profile with therapeutic area breadth and depth, exposure to cutting edge platforms and diversification of revenues in terms of assets and geographies Key growth drivers now contributing to 48% of Innovative Medicines sales; upcoming launches expected to lay the foundation for future salesexpansion Advancing leading pipeline based on scale, innovation and value which will fuel growth in the mid- to long-termand help offset patent cliffs Committed to driving consistent margin expansion, Innovative Medicinesexpected to reach high 30s in the mid-term. Target for Novartis Technical Operations productivity program starting in 2021 increased from USD 1.5bn to USD 2bn Laying the foundations for sectorleadership in the ESG space Initiating share buyback of up to USD 2.5bn, highlighting confidence in growth Basel, November24, 2020 — Novartis is hosting today its annual Meet Novartis Management event giving investors and industry analysts the opportunity to meet with ke

Awilco Drilling PLC: Awilco Drilling Reports Q3 2020 results24.11.2020 07:00:00 CETPress release

Awilco Drilling PLC reported contract revenue of USD 10.6 million (USD 6.4 million Q2), EBITDA USD 1.7 million (USD 1.5 million loss in Q2) and a net loss of USD 1.0 million (USD 4.6 million loss in Q2). Revenue efficiency was 100% during the standard day rate work in the quarter (Q2 fixed price work only). Operational uptime was 100% during the quarter during the standard day rate work in the quarter (Q2 fixed price work only). Contract backlog at the end of Q3 was approximately USD 15.2 million (USD 19.4 million Q2). Please see attached for the Q3 2020 report. A digital presentation will be held today, on 24 November 2020 at 12:00 UK time (13:00pm CET / 07:00 EST). The presentation will be available for download on the Investor Relations section (go to "Press Releases") at prior to the meeting. There will be a Q&A session after the presentation. To join the digital meeting, please click this link or copy and paste the following address into your browser: https:

ObsEva SA Submits Marketing Authorization Application to the European Medicines Agency for YSELTY® (linzagolix) for the Treatment of Women with Uterine Fibroids24.11.2020 07:00:00 CETPress release

If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options for the management of uterine fibroids: 100 mg once daily for women with a contraindication to or who prefer to avoid hormonal add-back therapy (ABT)200 mg once daily with concomitant ABT for long-term use (beyond 6 months)200 mg once daily for short-term use, in particular when rapid reduction in fibroid volume is desired ObsEva expects to submit a new drug application to U.S. Food and Drug Administration in 1H:21 GENEVA, Switzerland and BOSTON, MA (November 24, 2020) – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for YSELTY® (linzagolix 100mg and linzagolix 200mg) for the management of heavy menstrual bleeding (HMB) associated with uterine fibroids. “The MAA submission is a